HAYRİYE ORALLAR, ŞEYDA KARABÖRK, Şule AYDIN TÜRKOĞLU

Investigation of IL-17A, IL-17F, IL-34 Levels of Patient with Multiple Sclerosis and Pseudotumor Cerebri

Objective: Multiple Sclerosis is an inflammatory demyelinating disease characterized by lymphocyte infiltration and demyelination of brain tissue and central nervous system. Materials and Methods: This study aimed to evaluate the interleukin (IL-17A, IL-17F, and IL-34 cytokine) levels in the cerebrospinal fluid of Relapsing-Remitting Multiple Sclerosis (n=23), radiologically isolated syndrome (n=5) and pseudotumor cerebri (n=15) cases. In this study, lumbar puncture cerebrospinal fluid obtained from the patients who were diagnosed with Multiple Sclerosis aged between 21-55. The PTC group included patients with pseudotumor cerebri aged 28-60 years. The levels of IL-17A, IL-17F, IL-34 cytokines were determined by ELISA kit. Results: In this study, Among the studied cytokines in the cerebrospinal fluid samples of the patients, median (min-max) values of IL-17A for the Demyelinated group and pseudotumor cerebri group were 50 (7-257) pg/ml and 2 (1-6) pg/ml respectively, a statistically significant difference (p

PDF

___

[1] Compston A, Coles A. Multiple sclerosis. Lancet (London, England). 2008; 372(9648): 1502–1517.

[2] Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162–173.

[3] Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol. 2001; 14(3): 271–278.

[4] Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009; 72(9): 800–805.

[5] Andersson M, Alvarez-Cermeño J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry.1994; 57(8): 897–902.

[6] Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015; 15(9): 545–558.

[7] Dargahi N, Katsara M, Tselios T, et al. Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci. 2017; 7(7): 78.

[8] Van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebocontrolled, MR-monitored phase II trial. Neurology.1997; 49(2): 351–357.

[9] Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015; 14(2): 183–193.

[10] Van Langelaar J, Van der Vuurst de Vries RM, Janssen M, et al. T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. Brain. 2018; 141(5): 1334–1349.

[11] Stromnes IM, Cerretti LM, Liggitt D, et al. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med. 2008; 14(3): 337–342.

[12] Baghdadi M, Umeyama Y, Hama N, et al. Interleukin‐34, a comprehensive review. J Leukoc Biol. 2018; 104(5): 931-51.

[13] Sospedra, M, Martin, R. Immunology of Multiple Sclerosis. Semin Neurol. 2016; 36(2): 115–127.

[14] Truong AD, Hong Y, Lee J, et al. Interleukin-34 Regulates Th1 and Th17 Cytokine Production by Activating Multiple Signaling Pathways through CSF-1R in Chicken Cell Lines. Int J Mol Sci. 2018; 19(6): 1665.

[15] Portelli M, Papageorgiou PN. An update on idiopathic intracranial hypertension. Acta Neurochir (Wien). 2017; 159(3): 491–499.

[16] Friedman DI. The pseudotumor cerebri syndrome. Neurol Clin. 2014; 32(2): 363–396.

[17] Matejčíková Z, Mareš J, Sládková V, et al. Cerebrospinal fluid and serum levels of interleukin-8 in patients with multiple sclerosis and its correlation with Q-albumin. Mult Scler Relat Disord. 2017; 4: 12–15.

[18] Brucklacher-Waldert V, Stuerner K, Kolster M. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. 2009; 132(Pt 12): 3329–3341.

[19] Kebir H, Ifergan I, Alvarez JI. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol. 2009; 66(3): 390–402.

[20] Xie HH, Shen H, Zhang L, et al. Elevated Serum Interleukin-34 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity. Sci Rep. 2018; 8(1): 3462.

[21] Tian Y, Shen H, Xia L, et al. Elevated serum and synovial fluid levels of interleukin-34 in rheumatoid arthritis: possible association with disease progression via interleukin-17 production. J Interferon Cytokine Res. 2013; 33(7): 398‐01.

[22] Rahman M T, Ghosh C, Hossain M, et al. IFN-gamma, IL-17A, or zonulin rapidly increase the permeability of the bloodbrain and small intestinal epithelial barriers: relevance for neuro-inflammatory diseases. Biochem Biophys Res Commun. 2015; 129: 625-637.

[23] Huppert J, D. Closhen, A. Croxford, et al. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J. 2010; 24(4): 1023-34.

[24] Ni P, Dong H, Wang Y, et al. IL-17A contributes to perioperative neurocognitive disorders through blood-brain barrier disruption in aged mice J. Neuroinflammation.2018;15: 332

[25] Setiadi FA, Abbas AR, Jeet WK, et al. IL-17A is associated with the breakdown of the blood-brain barrier in relapsingremitting multiple sclerosis. J Neuroimmunol.2019; 332: 147-154.

[26] Felix J, Elegheert J, Gutsche I, et al. Human IL-34 and CSF-1 establish structurally similar extracellular assemblies with their common hematopoietic receptor. Structure. 2013; 21: 528-539.

[27] Nakamichi Y, Udagawa N, Takahashi N. IL-34 and CSF-1: similarities and differences. J Bone Miner Metab. 2013; 31: 486-495.

[28] Wang Y, Szretter KJ, Vermi W, et al. IL-34 is a tissuerestricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol. 2012; 13: 753-760.

[29] Wang Y, Colonna M. Interkeukin-34, a cytokine crucial for the differentiation and maintenance of tissue resident macrophages and Langerhans cells. Eur J Immunol.2014; 44:1575-1581

[30] Greter M, Lelios I, Pelczar P, et al. Stroma-derived interleukin-34 controls the development and maintenance of Langerhans cells and the maintenance of microglia. Immunity. 2012; 37:1050-1060

[31] Ge Y, Huang M, Yao Ym. Immunomodulation of Interleukin-34 and its Potential Significance as a Disease Biomarker and Therapeutic Target. Int J Biol Sci 2019; 15(9):1835-1845.